

Big Picture Perspectives on PMI (with emphasis on pharmacogenomics)

9:15am – 9:45am **Speaker 1: CDRH Adam Berger, PhD, FDA**
Big picture overview on PMI (emphasis on pharmacogenomics)



Adam C. Berger, Ph.D. is Senior Staff Fellow on the Personalized Medicine Staff at FDA's Office of In Vitro Diagnostics and Radiological. His primary interests focus on policy issues relating to translational medicine, including the development of drug, diagnostic, and clinical and public health applications. Dr. Berger has facilitated numerous public policy discussions and reports such as Genome-Based

Diagnostics: Clarifying a Pathway to Clinical Use; Integrating Large-Scale Genomic Information into Clinical Practice; Genome-Based Therapeutics: Targeted Drug Discovery and Development; and The Value of Genetic and Genomic Technologies.

Dr. Berger received his doctorate from Emory University in the Biochemistry, Cell and Developmental Biology Program, his B.S. in Molecular Genetics from The Ohio State University, and completed his postdoctoral training at the National Cancer Institute of the National Institutes of Health (NIH). He is the recipient of the NIH Fellows Award for Research Excellence and a Ruth L. Kirschstein National Research Service Award.

9:45am – 10:15am **Speaker 2: Julie Johnson, PharmD, University of Florida, College of Pharmacy**

Big picture from a pharmacy/pharmacist perspective with past, current and future vision for the use and integration of this technology in pharmacist-provided patient care and overall medication use.



Julie A. Johnson, Pharm.D., is Dean of the University of Florida College of Pharmacy and Distinguished Professor of Pharmacy and Medicine. She is also Director of the UF Health Personalized Medicine Program. She is a board certified pharmacotherapy specialist (BCPS) with added qualifications in cardiology.

Dr. Johnson's research focuses on cardiovascular pharmacogenomics and genomic medicine. She leads a hypertension pharmacogenomics research group, funded under the NIH Pharmacogenomics Research Network, and another NIH-funded group in genomic medicine implementation in the NIH IGNITE network. She is an internationally-recognized leader in cardiovascular pharmacogenomics and genomic medicine, with over 240 peer reviewed publications and > \$35M in research funding as principal investigator.

She was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other award.